{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"], "versionId": "22", "lastUpdated": "2025-08-08T16:22:06.949Z"}, "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/367931", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03640312-otherOutcomeMeasure-2--OG000", "assigner": {"display": "Computable Publishing LLC"}}], "name": "NCT03640312_otherOutcomeMeasure_2_OG000", "title": "Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312", "status": "active", "variableDefinition": [{"description": "QUARTET LDQT", "note": [{"text": "Outcome Measure Denominator Units: Participants"}], "variableRole": "population", "observed": {"identifier": {"type": {"text": "ClinicalTrials.gov Outcome Measurement Group Id"}, "value": "OG000"}, "display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}}, {"variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "NCT03640312-otherOutcome-2", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Rate of Adverse Events of Special Interest at 12 weeks -  (NCT03640312)", "reference": "EvidenceVariable/367898"}}], "statistic": [{"statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000047", "display": "count"}], "text": "Count of Participants"}, "quantity": {"value": 16, "unit": "Participants"}, "sampleSize": {"knownDataCount": 32}, "attributeEstimate": [{"type": {"text": "Percentage"}, "quantity": {"value": 50, "unit": "%"}}]}], "id": "367931", "url": "https://fevir.net/resources/Evidence/367931", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367931. Revised 2025-08-08. Available at: https://fevir.net/resources/Evidence/367931. Computable resource at: https://fevir.net/resources/Evidence/367931#json.", "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}